Home
Clinical Trials
ShortStop-HER2: 12 Months vs....

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Last Updated: 2026-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

1524 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-17

Study Completion Date

2037-03-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary and secondary objectives of the study:

PRIMARY OBJECTIVES:

I. To evaluate whether 6 months of combined neoadjuvant (neo)/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.

II. To compare the Functional Assessment of Cancer Therapy-Breast (FACT-B) total score at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life)

SECONDARY OBJECTIVES:

I. Secondary objectives are to evaluate whether 6 months compared to 12 months results in differences for the following:

Ia. Grade 3 or higher adverse event (AE) rates; Ib. Overall survival (OS); Ic. Locoregional recurrence (LRR, both isolated LRR as first events, and LRR events simultaneous with distant metastasis \[DM\]) incidence; Id. RFS for key subgroups: baseline stage, hormone receptor (HR) status, neoadjuvant chemotherapy backbone, and dual versus single HER2 blockade in the adjuvant setting; Ie. Time to central nervous system (CNS) recurrence (both isolated CNS recurrence as first events, and CNS recurrence events simultaneous with distant metastasis and/or LRR).

II. To compare the FACT-B total score at 18 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) III. To compare side effect bother as measured by the Functional Assessment of Cancer Therapy General Population 5 (FACT GP5) item at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) IV. To compare specific patient-reported symptomatic adverse events (i.e. diarrhea, constipation, fatigue, and rash) as measured by the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life)

QUALITY OF LIFE EXPLORATORY OBJECTIVES:

I. To examine the different FACT-B subscales at all other evaluable time points.

II. To examine heterogeneity of treatment effects within subgroups defined by subcutaneous versus intravenous treatment delivery.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive trastuzumab intravenously (IV) or subcutaneously (SC) on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multigated acquisition (MUGA) as well as mammography, ultrasound, or magnetic resonance imaging (MRI) throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial.

ARM 2: Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial.

After completion of study treatment, patients are followed up every 6 months for 5 years after registration or until recurrence and then annually for a total of 10 years after registration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Early Stage Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type OTHER

Ancillary studies

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients (females and males) with clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 (except T3N1 tumors, which are not eligible)
* Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Patients with residual isolated tumor cells at surgery are considered node-positive and are not eligible
* HER2+ by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Central pathology review is not required. In cases where there were multiple tumor sites in breast/nodes that had HER2 testing at diagnosis, at least one site must have been HER2+ AND the treating investigator must feel it is in the patient's best interest to be treated as having HER2+ breast cancer
* Known hormone receptor status as defined by ASCO/CAP guidelines. Estrogen receptor (ER) and progesterone receptor (PR) of any values are allowed. Hormone receptor positive status can be determined by either known positive ER or known positive PR status; hormone receptor negative status must be determined by both known negative ER and known negative PR
* If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts (including the requirement that at least one biopsied site on each side must have been HER2+)
* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Patients must have received neoadjuvant chemotherapy in combination with trastuzumab with or without pertuzumab for a minimum of 12 weeks. All chemotherapy must have been completed preoperatively

* Patient must complete a minimum of 12 weeks of coverage with trastuzumab and a maximum of 24 weeks in the combined neoadjuvant and adjuvant setting prior to trial registration. Trastuzumab may have been administered either weekly or once every 3 weeks (q3weeks). (For purposes of this eligibility criterion, a single dose of q3week trastuzumab would provide 3 weeks of coverage; a single dose of once a week (q1week) trastuzumab would provide 1 week of coverage. If a q3week dose of trastuzumab were administered and then the subsequent dose was delayed for any period of time, that would still count as 3 weeks of coverage.)
* Administration of endocrine therapy for treatment of this breast cancer is allowed prior to trial registration. If a patient received prior breast cancer endocrine therapy (eg tamoxifen or aromatase inhibitor) for DCIS or preventive indication, and endocrine therapy is indicated for treatment of their current breast cancer, then prior endocrine therapy must have been stopped \> 12 months prior to registration on this protocol
* No use of investigational anti-cancer agents at time of registration
* Patient must register within 14 weeks of final surgery
* Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows:

* Breast surgery: Total mastectomy with grossly negative margins (in the opinion of the surgeon there is no disease grossly at the margins) or breast-conserving surgery with histologically negative margins (no ink on tumor, including DCIS) unless those margins are anterior at the skin or posterior at the chest wall and no additional margin re-excision can be performed
* Lymph node surgery: Lymph node surgery must have been performed and can include sentinel lymph node biopsy, targeted axillary dissection, or axillary dissection, at the discretion of the breast surgeon
* Adequate radiation: Patients who completed breast-conserving surgery (i.e. lumpectomy) must have received or plan to receive adjuvant radiation. If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible. Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation) are not eligible

* Adjuvant radiation can be given on study, and in this case is encouraged to be given concurrently with adjuvant HER2-directed therapy, per investigator discretion
* Targeting of the regional nodal basins will be at treating investigator discretion
* Not pregnant and not nursing, because this study involves agents with known teratogenic potential. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test should be performed prior to receiving HER2-directed therapy according to local standard practice
* Adequate hepatic, renal and bone marrow function to receive adjuvant HER2-directed therapy in the opinion of the treating investigator. There are no specific required laboratory values for eligibility
* No stage IV (metastatic) breast cancer
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* No history of any prior (ipsilateral \[ipsi-\] or contralateral) invasive breast cancer. Prior DCIS is allowed
* No evidence of recurrent disease following preoperative therapy and surgery
* Patients living with HIV who are healthy and deemed by their medical team to have a low risk of AIDS-related illnesses are included in this trial. Patients with Hepatitis B or Hepatitis C virus who are healthy and deemed by their medical team to meet all other enrollment criteria are included in this trial.
* Patients with inadequate cardiac function on most recent assessment of left ventricular ejection fraction (LVEF) are not eligible for this trial. Inadequate cardiac function is defined as LVEF \< 50% on echocardiogram (echo) or multiple-gated acquisition (MUGA)
* No history of grade 3 or 4 toxicity related to trastuzumab. If pertuzumab is planned to be given on trial, patient must also have no history of grade 3-4 toxicity related to pertuzumab
* No contraindication to receipt of further HER2-directed therapy
* No patients with severe, uncontrolled systemic disease that may interfere with planned trial therapy.

Exclusion Criteria

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adrienne Waks, MD

Role: STUDY_CHAIR

Alliance for Clinical Trials in Oncology

Site Public Contact

Role: primary

530-332-4700

Role: primary

833-574-2273

Site Public Contact

Role: primary

[email protected]

877-827-8839

Site Public Contact

Role: primary

[email protected]

858-822-5354

Role: primary

916-734-3089

Site Public Contact

Role: primary

[email protected]

877-642-4691

Role: primary

530-582-6450

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

877-642-4691

Site Public Contact

Role: primary

[email protected]

720-874-1881

Site Public Contact

Role: primary

[email protected]

877-827-8839

Role: primary

202-444-2223

Site Public Contact

Role: primary

202-877-8839

Role: primary

309-779-2000

Site Public Contact

Role: primary

[email protected]

773-702-8222

Site Public Contact

Role: primary

[email protected]

800-446-5532

Site Public Contact

Role: primary

[email protected]

800-446-5532

Site Public Contact

Role: primary

[email protected]

217-876-4762

Site Public Contact

Role: primary

[email protected]

Role: primary

217-545-7929

Role: primary

515-956-4132

Site Public Contact

Role: primary

[email protected]

515-239-4734

Site Public Contact

Role: primary

515-241-3305

Site Public Contact

Role: primary

515-956-4132

Site Public Contact

Role: primary

[email protected]

316-291-4774

Role: primary

800-987-3005

Site Public Contact

Role: primary

[email protected]

207-396-8670

Site Public Contact

Role: primary

[email protected]

207-396-8670

Role: primary

800-888-8823

Site Public Contact

Role: primary

443-849-3706

Site Public Contact

Role: primary

443-777-7364

Site Public Contact

Role: primary

[email protected]

410-261-8151

Site Public Contact

Role: primary

443-643-3010

Site Public Contact

Role: primary

[email protected]

Site Public Contact

Role: primary

240-964-1400

Role: primary

218-786-3308

Site Public Contact

Role: primary

[email protected]

877-229-4907

Site Public Contact

Role: primary

[email protected]

218-786-3308

Site Public Contact

Role: primary

605-312-3320

Site Public Contact

Role: primary

[email protected]

218-786-3308

Site Public Contact

Role: primary

605-312-3320

Role: primary

314-996-5569

Site Public Contact

Role: primary

816-404-4375

Role: primary

314-996-5569

Site Public Contact

Role: primary

[email protected]

800-600-3606

Site Public Contact

Role: primary

[email protected]

800-600-3606

Site Public Contact

Role: primary

314-996-5569

Site Public Contact

Role: primary

[email protected]

800-600-3606

Site Public Contact

Role: primary

314-251-7066

Site Public Contact

Role: primary

314-996-5569

Role: primary

551-996-2897

Site Public Contact

Role: primary

[email protected]

215-600-9151

Site Public Contact

Role: primary

[email protected]

800-767-9355

[email protected]

503-215-2614

Role: primary

412-653-8100

Role: primary

717-741-9229

Site Public Contact

Role: primary

877-441-7957

Role: primary

[email protected]

Site Public Contact

Role: primary

[email protected]

804-628-6430

Role: primary

[email protected]

Role: primary

262-257-5100

Site Public Contact

Role: primary

414-805-3666

Role: primary

877-405-6866

Site Public Contact

Role: primary

414-805-0505

Site Public Contact

Role: primary

715-422-7718

Role: primary

787-763-1296

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2024-10478

Identifier Type: OTHER

Identifier Source: secondary_id

A012303

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

NCT00976989 COMPLETED PHASE2

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

NCT00629278 UNKNOWN PHASE3

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677 COMPLETED PHASE3

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

NCT02789657 COMPLETED PHASE2

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01566721 COMPLETED PHASE3

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT07043725 RECRUITING PHASE3

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

NCT00950300 COMPLETED PHASE3

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

NCT00545688 COMPLETED PHASE2

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

NCT02003209 COMPLETED PHASE3

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

NCT02586025 COMPLETED PHASE3

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

NCT03674112 COMPLETED PHASE2

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755 NOT_YET_RECRUITING PHASE2

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

NCT07246317 NOT_YET_RECRUITING PHASE2

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

NCT03556358 COMPLETED PHASE3

Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer

NCT06472583 RECRUITING PHASE2

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560 TERMINATED PHASE1

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

NCT04928261 ACTIVE_NOT_RECRUITING PHASE4

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

NCT00003440 COMPLETED PHASE3

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

NCT07057427 RECRUITING PHASE3

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT02131064 COMPLETED PHASE3

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

NCT02152943 COMPLETED PHASE1

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy

NCT02345772 TERMINATED PHASE1/PHASE2

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

NCT02162667 COMPLETED PHASE3

A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

NCT01572038 COMPLETED PHASE3

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747 RECRUITING PHASE2

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Study Results

Basic Information

Brief Summary

Related Clinical Trials

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Detailed Description

Conditions

Study Design

Study Groups

Arm 1 (12-month adjuvant therapy)

Trastuzumab (Herceptin)

Pertuzumab

Echocardiography

Multigated Acquisition Scan

Mammography

Ultrasound

Magnetic Resonance Imaging

Biospecimen Collection

Questionnaire Administration

Arm 2 (6-month adjuvant therapy)

Trastuzumab (Herceptin)

Pertuzumab

Echocardiography

Multigated Acquisition Scan

Mammography

Ultrasound

Magnetic Resonance Imaging

Biospecimen Collection

Questionnaire Administration

Interventions

Trastuzumab (Herceptin)

Pertuzumab

Echocardiography

Multigated Acquisition Scan

Mammography

Ultrasound

Magnetic Resonance Imaging

Biospecimen Collection

Questionnaire Administration

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

National Cancer Institute (NCI)

Alliance for Clinical Trials in Oncology

Responsible Party

Principal Investigators

Adrienne Waks, MD

Locations

Cancer Center at Saint Joseph's

Mercy Hospital Fort Smith

CARTI Cancer Center

Mission Hope Medical Oncology - Arroyo Grande

Mercy Cancer Center - Carmichael

Mercy San Juan Medical Center

Enloe Medical Center

Kaiser Permanente Dublin

Mercy Cancer Center - Elk Grove

Kaiser Permanente-Fremont

Kaiser Permanente Fresno Orchard Plaza

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

UC San Diego Moores Cancer Center

Fremont - Rideout Cancer Center

Mercy Cancer Center

Kaiser Permanente-Modesto

Kaiser Permanente-Oakland

UC Irvine Health/Chao Family Comprehensive Cancer Center

Mercy Cancer Center - Rocklin

Kaiser Permanente-Roseville

Kaiser Permanente Downtown Commons

Mercy Cancer Center - Sacramento

University of California Davis Comprehensive Cancer Center

Kaiser Permanente-South Sacramento

UC San Diego Medical Center - Hillcrest

Kaiser Permanente-San Francisco